Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604565 · ClinicalTrials.gov registry record · NA
Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients
A NA study, sponsored by Charles Drew University of Medicine and Science.
- Terminated
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT00604565 is a NA study that was terminated before completion, run by Charles Drew University of Medicine and Science. The registered enrollment target is 11 participants.
The verdict
NCT00604565, a NA study, was terminated before completion, sponsored by Charles Drew University of Medicine and Science.
- TERMINATED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
In maintenance hemodialysis patients, regular administration of parenteral iron by addition of soluble ferric pyrophosphate (SFP) to the dialysate, when compared to conventional dialysate, is effective in preventing the development of iron deficiency, thereby maintaining hemoglobin level; is clinically safe and does not lead to oxidative stress or inflammation.
Interventions
- OTHER placebo
- DRUG soluble ferric pyrophosphate (SFP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604565
The ClinicalTrials.gov registry entry for NCT00604565 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00604565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00604565 about?
NCT00604565 is a clinical study titled "Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients". In maintenance hemodialysis patients, regular administration of parenteral iron by addition of soluble ferric pyrophosphate (SFP) to the dialysate, when compared to conventional dialysate, is effective in preventing the development of iron deficiency, thereby maintaining hemoglobin level; is clinica...
What is the current status of trial NCT00604565?
This trial is currently terminated. It is a NA study. The enrollment target is 11 participants. The study started on 2008-01. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00604565?
The interventions under investigation include: placebo (OTHER), soluble ferric pyrophosphate (SFP) (DRUG).
Who is sponsoring clinical trial NCT00604565?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.